Three Common Medicines Classified as Carcinogenic by IARC: What Patients Need to Know Before Stopping Treatment

A new cancer classification involving three widely used medicines has understandably raised an alarming question: if hydrochlorothiazide, voriconazole and tacrolimus are now classified as carcinogenic to humans, should patients stop taking them?

The short answer is no—not without medical advice.

The International Agency for Research on Cancer (IARC), the specialised cancer research agency of the World Health Organization, has classified all three medicines as Group 1, “carcinogenic to humans.” The finding is based on an evaluation of human epidemiological evidence, experimental studies and mechanistic evidence. IARC’s Volume 137, published in 2026, contains the detailed assessments. :contentReference[oaicite:0]{index=0}

But there is an important distinction that can easily disappear in a frightening headline: IARC classifies carcinogenic hazards; it does not say that everyone exposed to a Group 1 agent will develop cancer, nor does the classification by itself determine whether a medicine’s benefits outweigh its risks for a particular patient.

That distinction is especially important because these are not obscure drugs. Hydrochlorothiazide is a commonly used blood-pressure medicine, voriconazole is used against potentially life-threatening invasive fungal infections, and tacrolimus is essential to preventing rejection after organ transplantation. All three are included in the WHO Model List of Essential Medicines. :contentReference[oaicite:1]{index=1}

What exactly did IARC classify?

The classification applies to hydrochlorothiazide, voriconazole and tacrolimus as exposures from medical treatment. IARC’s expert Working Group concluded that there was sufficient evidence of cancer in humans for each of the three medicines. Tacrolimus also had supporting evidence from experimental animals and strong mechanistic evidence. :contentReference[oaicite:2]{index=2}

The three medicines are very different drugs, however. They should not be treated as though they carry the same type or magnitude of cancer risk.

• Hydrochlorothiazide: a thiazide diuretic widely used for hypertension and sometimes fluid retention.
• Voriconazole: a broad-spectrum triazole antifungal used for serious infections such as invasive aspergillosis.
• Tacrolimus: an immunosuppressant used mainly to prevent rejection after solid-organ transplantation and in certain other transplant settings; topical formulations are also used for some inflammatory skin conditions.

The reason for grouping them together in the IARC announcement is their hazard classification, not because they have identical biological effects or identical cancer risks.

What does “Group 1 carcinogenic” actually mean?

This is the most important concept for patients to understand.

IARC’s Group 1 category means that there is sufficient evidence that an agent can cause cancer in humans. It is a classification of hazard.

Hazard and risk are not the same thing.

A hazard asks: Can this exposure cause cancer?

Risk asks: How likely is cancer to occur for a particular person under particular conditions of exposure?

The difference is crucial. Cancer risk can depend on factors such as dose, duration of exposure, route of exposure, underlying disease, other treatments, age, ultraviolet exposure and individual susceptibility.

Therefore, seeing the words “Group 1” should not be interpreted as “this medicine will cause cancer.” It means that the evidence is strong enough for IARC to identify the exposure as carcinogenic to humans.

Why IARC’s classification is not a prescription decision

IARC’s role is to evaluate whether exposures can cause cancer. It is not the same as a regulatory authority deciding whether a medicine should remain available or a physician deciding whether an individual patient should continue treatment.

That distinction becomes particularly important with medicines that treat serious or potentially fatal conditions.

For someone with uncontrolled hypertension, suddenly abandoning an effective blood-pressure medicine can create immediate cardiovascular risks. For a person with invasive fungal disease, stopping an effective antifungal without an alternative could allow a dangerous infection to progress. For an organ-transplant recipient, abruptly interrupting immunosuppression can place the transplanted organ at serious risk of rejection.

The relevant medical question is therefore not simply “Is this drug carcinogenic?” It is “What is the balance between this patient’s treatment benefits, cancer-related risks and available alternatives?”

Hydrochlorothiazide: why the blood-pressure medicine attracted attention

Hydrochlorothiazide is a thiazide diuretic that helps lower blood pressure partly by increasing the excretion of sodium and water. It has been used for decades and is also frequently combined with other antihypertensive medicines in a single tablet.

IARC’s evaluation found sufficient evidence that hydrochlorothiazide causes squamous cell carcinoma of the skin and cancer of the lip in humans. The evidence was considered limited for possible associations with several other skin cancers, including basal cell carcinoma, melanoma, Merkel cell carcinoma and malignant adnexal tumours. :contentReference[oaicite:3]{index=3}

One important biological clue is the medicine’s interaction with ultraviolet radiation. IARC notes that hydrochlorothiazide is phototoxic, meaning that its molecular properties can interact with ultraviolet radiation. :contentReference[oaicite:4]{index=4}

This provides an important practical insight: the concern is particularly relevant to skin cancer, rather than suggesting that hydrochlorothiazide broadly causes every type of cancer.

Why sunlight matters in the hydrochlorothiazide story

Patients taking hydrochlorothiazide should not interpret the IARC finding as a reason to panic about ordinary outdoor activity. Rather, it reinforces the importance of sensible protection from excessive ultraviolet exposure.

People can reduce ultraviolet exposure through measures such as seeking shade, using protective clothing and applying appropriate sunscreen when exposed to sunlight.

This does not replace medical advice about the medicine itself. A patient who has been taking hydrochlorothiazide for years should discuss the new information with their doctor, particularly if they have a history of skin cancer, substantial cumulative sun exposure or other relevant risk factors.

The key point is that the cancer classification creates a reason for informed medical review—not a reason for unsupervised treatment interruption.

Voriconazole: a different cancer concern in a very different patient population

Voriconazole presents a completely different clinical situation.

It is a broad-spectrum antifungal medicine used for serious fungal infections, including invasive aspergillosis. These infections can be life-threatening, particularly in people whose immune systems are compromised.

IARC found sufficient evidence that voriconazole causes squamous cell carcinoma of the skin in humans. The agency also found strong mechanistic evidence involving oxidative stress and changes in cell proliferation, cell death or nutrient supply, particularly in connection with ultraviolet radiation. :contentReference[oaicite:5]{index=5}

Voriconazole and its major metabolite, voriconazole N-oxide, have phototoxic properties. This is an important part of understanding why long-term exposure can raise particular concerns about skin cancer. :contentReference[oaicite:6]{index=6}

Why stopping voriconazole can be especially dangerous

Imagine a patient being treated for an invasive fungal infection. The medicine may be doing something far more immediate than preventing a future health problem: it may be controlling an infection that could otherwise become life-threatening.

That changes the risk calculation dramatically.

The appropriate response to a carcinogenicity finding is therefore not automatically to discontinue treatment. Physicians may instead consider the duration of therapy, the severity of the fungal infection, alternative antifungal options, the patient’s individual risk factors and strategies to reduce ultraviolet exposure.

In some patients, the benefits of effective antifungal therapy can be substantial and immediate.

A long-term potential cancer hazard and a short-term risk from an uncontrolled invasive infection cannot simply be placed on the same scale without considering the clinical context.

Tacrolimus: why immunosuppression changes the equation

Tacrolimus is perhaps the clearest example of why “carcinogenic” does not automatically mean “stop taking it.”

The medicine suppresses immune activity and is widely used to prevent rejection after solid-organ transplantation. It is also used in specific settings involving prevention of graft-versus-host disease, while topical tacrolimus has uses in certain inflammatory skin conditions. :contentReference[oaicite:7]{index=7}

IARC found sufficient evidence that tacrolimus causes non-Hodgkin lymphoma and post-transplant lymphoproliferative disorder in humans. Evidence was considered limited for associations with leukaemia and squamous cell carcinoma of the skin. :contentReference[oaicite:8]{index=8}

For tacrolimus, the biological explanation is particularly important. Suppressing the immune system can reduce the body’s immune surveillance of abnormal cells and alter mechanisms involved in tumour control. IARC also identified mechanistic evidence involving immunosuppression, oxidative stress and genotoxicity in experimental systems. :contentReference[oaicite:9]{index=9}

The transplant paradox: a drug can carry a cancer risk and still be essential

Tacrolimus illustrates one of the hardest realities in modern medicine: the safest decision is not always the one that eliminates every long-term risk.

A transplant recipient depends on immunosuppressive therapy because the immune system can recognise the transplanted organ as foreign and attack it.

Reducing immunosuppression too aggressively may increase the risk of rejection. But maintaining immunosuppression can increase susceptibility to certain infections and malignancies.

Doctors therefore aim for a carefully controlled balance.

This is a recurring principle throughout medicine. Many effective treatments work precisely because they alter powerful biological processes. The goal is to achieve enough therapeutic effect to control disease while limiting unwanted effects.

Why these three medicines cannot be ranked by “danger”

A common mistake would be to read the IARC announcement as though the three medicines form a simple list from least dangerous to most dangerous.

They do not.

Consider the fundamentally different circumstances in which they are used:

• Hydrochlorothiazide: commonly used to control a chronic cardiovascular risk factor, with treatment alternatives available for many patients.
• Voriconazole: often used when clinicians are dealing with serious fungal infections in medically vulnerable patients.
• Tacrolimus: used to control immune rejection and can be essential for maintaining a transplanted organ.

The consequences of stopping treatment can therefore vary enormously.

This is precisely why an IARC hazard classification should be interpreted alongside clinical guidelines, treatment alternatives and individual patient circumstances.

What evidence did IARC examine?

IARC’s evaluation was not based on a single study.

The Working Group reviewed several categories of evidence, including epidemiological studies in humans, cancer bioassays in experimental animals and mechanistic studies. :contentReference[oaicite:10]{index=10}

This multidisciplinary approach is important because no single type of evidence can answer every question about carcinogenicity.

Human epidemiological studies can reveal associations between exposure and cancer in real-world populations. Animal studies can help investigate biological effects under controlled conditions. Mechanistic studies can explore how an exposure might contribute to cancer development at the cellular or molecular level.

Combining these evidence streams allows scientists to assess the overall weight of evidence rather than relying on one headline-generating result.

What patients taking these medicines should do

For people currently taking one of these medicines, the most useful response is calm and practical.

• Do not stop a prescribed medicine suddenly on your own.
• Ask your doctor or pharmacist whether the new IARC classification changes your individual treatment plan.
• Do not replace the medicine with an alternative without professional guidance.
• Discuss your personal cancer risk factors, treatment duration and possible alternatives where appropriate.
• Pay particular attention to sun protection if you are taking a medicine associated with photosensitivity or skin-cancer concerns.
• Continue necessary monitoring recommended for your underlying condition.

For transplant recipients especially, medication changes should be handled by the transplant-care team because immunosuppression needs to be carefully managed.

Does the IARC finding mean these medicines should be banned?

No.

IARC’s classification is a scientific assessment of carcinogenic hazard. It does not automatically mean that a medicine should be removed from clinical use.

In fact, the continued clinical importance of these medicines highlights why medical risk assessment cannot be reduced to a single label.

Hydrochlorothiazide can help control hypertension, a condition that itself can cause severe cardiovascular complications if inadequately treated. Voriconazole can treat serious fungal infections. Tacrolimus can protect transplanted organs from immune rejection.

The appropriate question is therefore whether a patient’s treatment remains justified given the known benefits, risks and alternatives.

The bigger lesson: “carcinogenic” is not the same as “equally risky”

This may be the most important insight missing from many discussions of the IARC classification.

Two agents can both belong to Group 1 while having very different exposure patterns, mechanisms, target cancers and practical risk profiles.

IARC’s classification system is designed to identify hazards, not to produce a league table of cancer risks.

That distinction is essential for interpreting pharmaceutical safety information. A medicine taken for years at a particular dose is a very different exposure from a chemical encountered briefly in another context. Route of administration can matter. Duration can matter. Patient characteristics can matter. Co-exposures can matter.

Therefore, a Group 1 label should trigger informed attention rather than automatic fear.

What this means for hypertension treatment in India

The hydrochlorothiazide finding is particularly relevant in India because hypertension is widespread and thiazide-type medicines are inexpensive and familiar components of blood-pressure treatment.

For patients taking hydrochlorothiazide, the conversation should therefore be about risk management rather than abrupt discontinuation.

A doctor may consider whether hydrochlorothiazide remains appropriate, whether another blood-pressure medicine would provide a comparable benefit, and what individual factors influence the decision.

The answer will not necessarily be the same for every patient.

Someone whose blood pressure is well controlled on a combination containing hydrochlorothiazide may have a different risk-benefit calculation from someone starting treatment for the first time. A patient with a history of skin cancer may also warrant a different discussion from someone without that history.

A new chapter in medicine: balancing treatment against long-term harm

The IARC classification highlights a broader challenge facing modern medicine.

As treatments become more effective, patients often live long enough for previously less visible long-term adverse effects to become detectable. Large populations and long follow-up periods can reveal risks that were difficult to identify when a medicine was first introduced.

That does not necessarily mean earlier medicine was careless. It reflects the reality that scientific knowledge changes as evidence accumulates.

The appropriate response is to update clinical decision-making as new evidence becomes available.

For these three drugs, that means clinicians now have a clearer picture of specific cancer hazards and can incorporate that information into conversations about treatment duration, monitoring, prevention and alternatives.

Conclusion: What the IARC classification really means

Hydrochlorothiazide, voriconazole and tacrolimus have been classified by IARC as Group 1 carcinogens because the available evidence supports their ability to cause cancer in humans. The classification is scientifically significant, but it should not be translated into the simplistic message that everyone taking these medicines is destined to develop cancer.

The three medicines have very different purposes and very different clinical contexts. Hydrochlorothiazide is used extensively for hypertension; voriconazole can be critical in treating severe fungal infections; and tacrolimus can be essential for preventing organ-transplant rejection.

The most important distinction is between hazard and individual risk. IARC identifies carcinogenic hazards. Doctors must determine how those hazards affect an individual patient’s treatment decision by considering benefits, exposure, alternatives and the consequences of stopping therapy.

For patients, the message is therefore straightforward: do not stop hydrochlorothiazide, voriconazole or tacrolimus simply because of the IARC announcement. Instead, discuss the finding with the clinician managing the condition for which the medicine was prescribed.

The real value of the new classification is not to frighten patients away from effective treatment. It is to give doctors and patients better information with which to make increasingly precise, evidence-based decisions about the balance between treating disease today and protecting health over the long term.